BR Biomedical Reports 2049-9434 2049-9442 D.A. Spandidos 10.3892/br.2017.1015 BR-0-0-1015 Articles Low levels of linoleic acid and α-linolenic acid and high levels of arachidonic acid in plasma phospholipids are associated with hypertension TsukamotoIkuyo 1 2 SugawaraShiori 1 3 Department of Food Science and Nutrition, Nara Women's University, Kitauoya-Nishimachi, Nara 630-8506, Japan Faculty of Clinical Nutrition, Hiroshima International University, Hirokoshingai, Kure, Hiroshima 737-0112, Japan Department of Health and Nutrition, Sendai Shirayuri Women's College, Honda-Cho, Izumi-ku, Sendai 981-3107, Japan Correspondence to: Professor Ikuyo Tsukamoto, Faculty of Clinical Nutrition, Hiroshima International University, 5-1-1 Hirokoshingai, Kure, Hiroshima 737-0112, Japan, E-mail: itsuka@cc.nara-wu.ac.jp; itsuka@ps.hirokoku-u.ac.jp 01 2018 08 11 2017 8 1 69 76 11092017 10102017 Copyright © 2018, Spandidos Publications 2018

Dietary fat is an important determinant in the development and progression of high blood pressure (BP), a major risk factor for cardiovascular diseases and mortality. The aim of the present study was to determine the association between plasma phospholipid fatty acids and hypertension in Japanese men. The plasma level of linoleic acid (LA) in the subjects with hypertension (systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg) was identified to be significantly higher than that in the healthy controls. Following adjustment for age, body mass index, physical activity, smoking status, alcohol consumption, salt intake, and serum levels of glucose and hemoglobin A1c, higher plasma levels of LA and α-linolenic acid (ALA), and lower levels of arachidonic acid (AA) were significantly associated with a lower prevalence of hypertension. The odds ratio (OR) for the highest quartile (Q4) versus the lowest quartile (Q1) of LA was 0.17 (P=0.003), the OR for Q4 versus Q1 of ALA was 0.26 (P=0.042) and the OR for Q4 versus Q1 of AA was 2.04 (P=0.047). These results indicate that elevated levels of LA and ALA, and reduced levels of AA in the plasma prevent hypertension.

 hypertension plasma fatty acid α-linolenic acid linoleic acid arachidonic acid Introduction

High blood pressure (BP) is a major risk factor for cardiovascular diseases and mortality. The progressive increase in BP over time is directly linked to vascular aging, characterized by endothelial dysfunction, arterial stiffening and inflammation (1).

Preventing the increase in BP is a major health problem globally, particularly in Japan with its increasing number of elderly people.

Dietary fat is an important determinant in the development and progression of high BP. Animal studies have demonstrated that diets high in saturated fatty acid (SFA) increase BP (2,3), whereas diets enriched with n-3 polyunsaturated fatty acid (PUFA) protect against BP elevation (4–6). However, epidemiologic evidence regarding the association between various subtypes and individual FA intake, and the risk of developing hypertension remains limited and inconsistent (7–9). No significant correlations have been observed between hypertension and intakes of SFA and PUFA (7,8). However, higher SFA and lower PUFA consumption have been associated with higher BP (9). A summary of the International Study of Macro/Micronutrients and Blood Pressure (INTERMAP) reported that total PUFA, linoleic acid (LA), total n-3 FA, and α-linolenic acid (ALA), were inversely associated with BP (10). Data from meta-analyses (11,12) and clinical trials (13,14) have indicated that n-3 PUFA supplementation dose-dependently reduces BP in hypertensive patients, but not in normotensive individuals. A large-scale, population-based INTERMAP indicated that dietary intake of n-3 PUFA was inversely associated with BP levels in middle-aged normotensive individuals (15). A potential reason for the inconsistencies across studies may be attributable to the limited reliability of dietary measurement.

In contrast to dietary questionnaires, the FA composition of plasma cholesterol esters, phospholipids (PL), or the erythrocyte membrane is a reasonably accurate, objective measure that reflects dietary consumption and relevant biological processes (16–20). The serum/plasma levels of PUFA were significantly correlated with the intake of polyunsaturated fat (16), while its levels of 14:0, 16:0, 18:0, and monounsaturated FA may reflect a diet rich in saturated fat, due to their high correlations with saturated fat (19). Prior observational studies examined associations between serum/plasma or erythrocyte membrane FA and BP. However, their findings were controversial (21–26). Stearic acid, palmitoleic acid, n-9 eicosatrienoic acid, and dihomogammalinoleic acid in serum cholesterol esters (21), or total fatty acids, SFA, and LA in plasma PL were indicated to be associated with BP (22). Hypertensive men had lower C22:6/C20:5 [n-3 δ-6 desaturase (D6D) index], PUFA and polyunsaturated/saturated fatty acid (P/S) ratios in their serum free FA composition (24). Reduced levels of LA and P/S ratio, and elevated levels of palmitic acid and arachidonic acids (AA) in plasma cholesterol esters were associated with a higher risk of hypertension (23). A higher P/S ratio in the erythrocyte membrane is associated with the risk of hypertension in middle-aged and older women (25). Erythrocyte long-chain (LC) n-3PUFA (3) or LA (26) was associated with reduced BP levels. Thus, there is need for further investigation to elucidate the differential effects of FA on BP.

In this study, to obtain a dietary recommendation for preventing hypertension, the association between plasma FA composition and estimated desaturase activity, and hypertension was investigated in Japanese men.

 Materials and methods <sec> <title>Subjects

The study population comprised of 315 Japanese men (52.2±7.3 years old) who participated in a health examination conducted in 2007, 2008, 2009, 2011 and 2013 at the Nara Health Promotion Center (Nara, Japan). All participants who had received and were presently receiving medical treatment and medication for cancer, hypertension, diabetes, dyslipidemia or cardiovascular disease were excluded following a face-to-face interview with a physician. The study was designed in accordance with the principles of the Declaration of Helsinki of the World Medical Association and approved by the Ethics Committee of Nara Women's University (Nara, Japan). At the time of enrollment, written informed consent was obtained from each participant.

 Measurement

The questionnaires were administered to the participants. The participants underwent routine health examinations, anthropometric and BP measurements, and the collection of fasting blood samples. A face-to-face interview was conducted by trained interviewers using questionnaires about the medical condition, medication use, lifestyle of physical activity (>30 min of exercise or 1 h of walking per day), present smoking, and alcohol drinking (≥20 g ethanol per day) and a previously validated food frequency questionnaire (59).

 Anthropometry

The body mass index (BMI) was calculated as the body weight (kg) divided by the square of the height (m). The waist circumference (WC) was measured using an anthropometric measuring tape at a horizontal plane midway between the lowest rib and the iliac crest. BP was measured in triplicate with a validated semi-automatic sphygmomanometer after a minimum of 5 min rest in a seated position, in a quiet room, with no physical activity in the preceding half hour.

 Laboratory measurements

All serum and plasma samples were obtained in the fasted state. Routine clinical parameters, such as serum triacylglycerol, total cholesterol, low-density lipoprotein (LD)-cholesterol, high-density lipoprotein (HDL)-cholesterol, fasting blood glucose, fasting insulin, and hemoglobin (Hb)A1c were measured. The insulin resistance index was calculated according to the homeostasis model assessment (HOMA-IR) where HOMA-IR = fasting insulin (µU/ml) × fasting glucose (mg/dl)/405.

 FA analysis

Plasma was separated by centrifugation of fasting blood samples containing ethylenediaminetetraacetic acid-2Na for 15 min at 1,600 × g at 4°C, and stored at −80°C. Total lipids were extracted from the plasma according to the method of Bligh and Dyer (27). PL were separated by thin-layer chromatography using silica gel plates (Silica Gel 60; Merck KGaA, Darmstadt, Germany) with a solvent system of petroleum ether to ethylether to acetic acid (80:20:1; v/v/v). The spot corresponding to PL was scraped from the plate and transmethylated with 2 ml acetyl chloride: methanol (5:50; v/v) at 90°C for 2 h. Heptadecanoic acid (17:0) served as an internal standard. FA methyl esters were analyzed by gas-liquid chromatography (GC-2014; Shimadzu Corp., Kyoto, Japan) with a 25 m × 0.5 mm capillary column (HR-SS-10; Shinwa Chemical Industries Ltd., Kyoto, Japan) as previously described (28).

 Estimation of desaturase activity

The estimated desaturase activity was calculated by the ratio of the FAs in serum PL as follows: δ-9 desaturase activity (D9D) = [16:1 n-7/16:0], δ-6 desaturase (D6D) = [18:3 n-6/18:2 n-6] and δ-5 desaturase (D5D) = [20:4 n-6/20:3 n-6].

 Statistical analysis

Statistical analyses were performed using SPSS software version 23.0 (IBM, Inc., Armonk, NY, USA). All statistical tests were two-sided and P<0.05 was considered to indicate a statistically significant difference. Continuous data were expressed as the mean ± standard deviation (SD). The distribution of continuous variables was examined for normality by Shapiro-Wilk's test. Categorical data were expressed as a proportion (%). Differences in the continuous and categorical variables between two groups was examined using an unpaired Student's t-test (normally distributed data) or the Mann-Whitney U test (non-normally distributed data) and by the Chi-square test, respectively.

Logistic regression analysis was performed to calculate the odds ratios (OR) and 95% confidence intervals (CIs) to examine the associations between the prevalence of hypertension across quartiles of plasma PL FA and estimated desaturase activities considering the lowest quartile as the reference and controlling for potential confounding factors (age, BMI, physical activity, smoking status, alcohol drinking, salt intake, and serum levels of glucose and HbA1c).

 Results <sec> <title>Characteristics of subjects

The subjects were 35 to 77 years old (those in their thirties, forties, fifties, sixties, and seventies were 12, 106, 155, 39, and 3 men, respectively). Of the total population, 61.0, 7.9 and 13.3% were overweight or obese (BMI ≥25), had diabetes (fasting glucose ≥126 mg/dl), or were elderly (age ≥60), respectively. The subjects were divided into two groups as follows: Hypertension (systolic BP; SBP ≥140 mmHg and/or diastolic BP; DBP ≥90) and normal. The characteristics of the two groups, normal (n=246) and hypertension (n=69) are presented in Table I. As expected, the SBP and DBP of the hypertension group were significantly higher than those of the normal group. However, age, BMI, WC, and lifestyle, such as physical activity, present smoking, alcohol consumption and salt intake were not significantly different between the two groups.

In addition, the clinical data of the subjects are presented in Table I. The indicators of lipid metabolism, the values of triacylglycerol, total cholesterol, HDL-cholesterol and LDL-cholesterol, were not significantly different between the two groups. The values of fasting glucose and HbA1c in the hypertension group were significantly higher than those in the normal group, but their values were standard levels. The HOMA-IR values of the two groups were similar.

 FA composition of plasma PL

The FA composition of plasma PL in the two groups is presented in Table II. The level of LA was significantly lower in the hypertension than in the normal group. Except for LA, the levels of other FAs and the estimated desaturase activities did not differ significantly between the two groups.

 Associations between hypertension and plasma PL FA

To determine the associations between the prevalence of hypertension across quartiles of plasma PL FA and estimated desaturase activities, considering the lowest quartile as the reference, logistic regression analysis was performed. The OR associated with hypertension by quartiles of plasma FA proportions and estimated desaturase activities are presented in Table III. In a crude regression model, a higher quartile of LA was associated with a decreased prevalence of hypertension. The analysis indicated that the increase in the mean LA levels (from 15 to 21 mol%) decreased the prevalence of hypertension to 39%. Following adjustment for age, BMI, lifestyle, and serum levels of fasting glucose and HbA1c, higher quartiles of LA and ALA acid were significantly associated with a lower prevalence of hypertension, while the higher quartile of AA was associated with a higher prevalence of hypertension. The adjusted model demonstrated that the 1.4-times increase in the mean LA level (from 15 to 21 mol%) or 3.3-times increase in the mean ALA level (from 0.13 to 0.43 mol%) decreased the prevalence of hypertension to 17 or 26%, respectively. Conversely, the 1.5 times elevation of the mean AA level (from 5.68 to 8.47 mol%) increased the prevalence of hypertension to 2-fold.

 Discussion

The present study demonstrated that the plasma level of LA in the subjects with hypertension was significantly higher than that in those without hypertension. Furthermore, logistic regression analysis demonstrated that higher quartiles of LA were associated with a lower prevalence of hypertension. The 1.4 fold increase in the mean levels of LA decreased the prevalence of hypertension to 0.39 and 0.17 fold in a crude model, and in the adjusted for age, BMI, lifestyle associated factors, and serum levels of fasting glucose and HbA1c, respectively. Previous studies have identified dietary (10) and plasma/erythrocyte membrane levels of LA (22,23,26) to be inversely associated with BP, although the results are inconsistent (3,24,25). The possibility of detecting an association between LA and BP may be limited by imprecise measures of dietary LA, the sample size, and the degree of statistical control for potential confounders. However, consistent with the present results, animal studies indicate that LA may reduce the BP by serving as a substrate for vasoactive prostaglandins (29) and promote the relaxation of vascular smooth muscle cells (30).

After adjusting for the confounding factors, logistic analysis indicated that higher quartiles of ALA, the essential n-3 PUFA, were associated with a lower prevalence of hypertension. Consistently, the mean BP was reported to be inversely associated with the dietary intake of ALA in a cross-sectional Finnish study (31), and the concentration of adipose tissue linolenic acid (32). However, ALA supplementation led to no significant difference in BP changes between participants taking supplementation compared with the placebo control groups (33). ALA may be converted to eicosapentaenoic acid [EPA; 20:5n-3], but only in a small percentage and the conversion of EPA to docosahexaenoic acid [DHA; 22:6n-3], if any, is particularly limited in mammals (34). These findings indicate that the effect of ALA would not be mediated by EPA and DHA. It has been reported that ALA, as well as oleic acid and LA affects the structure of the cell membrane and regulates cell function (35). The effects of ALA on the cell membrane, at least partially, may explain its association with BP (35,36).

The long-chain n-3 fatty acids, EPA and DHA are considered to have an antihypertensive effect attributed to anti-inflammatory n-3 PUFA metabolites in eicosanoid/prostaglandin metabolism. EPA and DHA share the same metabolic pathways of AA and their competition with AA may decrease thromboxane A2 production, thus shifting the balance between thromboxaneA2 and prostacyclin I2 toward a more favorable vasodilatory condition. Epidemiological and clinical data demonstrate that a high dietary intake of fish oil (EPA and DHA) may have beneficial effects on cardiovascular health and be associated with lower SBP and DBP (37,38).

However, in the present study, neither EPA nor DHA was significantly associated with hypertension. This was also in contrast to some reports from clinical trials that dietary supplementation with fish oil (predominantly EPA and DHA) reduced BP in individuals with untreated hypertension, as well as numerous clinical and experimental studies (23). Recently, however, a review reported that current evidence supported the hypothesis that dietary supplementation of n-3 PUFA decreased the BP levels significantly only in hypertensive patients who showed an increase in the cell membrane content of these FAs, and this effect of n-3 PUFA on the BP was rather mild and not dose-associated (39).

A higher level of AA was associated with an increase in the prevalence of hypertension after adjusting for the confounding factors during logistic analysis in the present study. The Atherosclerosis Risk In Communities study indicated that a lower plasma LA level and higher plasma levels of palmitic acid and AA were associated with a higher risk of hypertension (23). AA may act through changes in eicosanoid/prostaglandin metabolism and the balance between thromboxane A2 (a vasoconstrictor agent) and prostacyclin (a vasodilating agent).

There were a number of limitations in the present study. As the participants were limited to Japanese men, our findings may not be generalizable to other populations. Due to the relatively small sample size, it is possible that associations between other FAs and BP may have been detectable in a larger study. Although the confounding variables were controlled, the possibility that unknown or unmeasured confounders account for the observed associations cannot be ruled out. Finally, the cross-sectional design of the present study mandates that inferences regarding causality be made with caution.

In conclusion, two essential FAs (LA and ALA) and AA were associated with hypertension. Higher plasma levels of LA and ALA, and lower levels of AA were associated with the reduced prevalence of hypertension. The plasma levels of these FAs reflect the dietary intakes (16–19), indicating that higher intakes of LA and ALA, and lower intakes of AA, prevent an increase in BP. Thus, dietary intake of FAs may be an important determinant in the prevention of hypertension.

 Acknowledgements

The authors would like to thank the clinical support of Dr Takemi Akahane and Dr Kennichi Fukui of the Nara Health Promotion Center.

 Abbreviations AA

arachidonic acid

 ALA

α-linolenic acid

 BMI

body mass index

 BP

blood pressure

 DHA

docosahexaenoic acid

 EPA

eicosapentaenoic acid

 LA

linoleic acid

 MUFA

monounsaturated fatty acid

 FA

fatty acid

 OR

odds ratio

 PL

phospholipid

 PUFA

polyunsaturated fatty acid

 SFA

saturated fatty acid

 References SunZAging, arterial stiffness, and hypertensionHypertension65252256201510.1161/HYPERTENSIONAHA.114.03617 GerberRTHolemansKO'Brien-CokerIMalletAIvan BreeRVan AsscheFAPostonLCholesterol-independent endothelial dysfunction in virgin and pregnant rats fed a diet high in saturated fatJ Physiol517607616199910.1111/j.1469-7793.1999.0607t.x ZengFFSunLLLiuYHXuYGuanKLingWHChenYMHigher erythrocyte n-3 PUFAs are associated with decreased blood pressure in middle-aged and elderly Chinese adultsJ Nutr14412401246201410.3945/jn.114.192286 RousseauDMoreauDRaederstorffDSergielJPRuppHMuggliRGrynbergAIs a dietary n-3 fatty acid supplement able to influence the cardiac effect of the psychological stress?Mol Cell Biochem178353366199810.1023/A:1006813216815 RousseauDHéliès-ToussaintCRaederstorffDMoreauDGrynbergADietary n-3 polyunsaturated fatty acids affect the development of renovascular hypertension in ratsMol Cell Biochem225109119200110.1023/A:1012266005428 RousseauDHéliès-ToussaintCMoreauDRaederstorffDGrynbergADietary n-3 PUFAs affect the blood pressure rise and cardiac impairments in a hyperinsulinemia rat model in vivoAm J Physiol Heart Circ Physiol285H1294H1302200310.1152/ajpheart.00651.2002 WittemanJCWillettWCStampferMJColditzGASacksFMSpeizerFERosnerBHennekensCHA prospective study of nutritional factors and hypertension among US womenCirculation8013201327198910.1161/01.CIR.80.5.1320 AscherioARimmEBGiovannucciELColditzGARosnerBWillettWCSacksFStampferMJA prospective study of nutritional factors and hypertension among US menCirculation8614751484199210.1161/01.CIR.86.5.1475 LivingstoneKMGivensDICockcroftJRPickeringJELovegroveJAIs fatty acid intake a predictor of arterial stiffness and blood pressure in men? Evidence from the Caerphilly Prospective StudyNutr Metab Cardiovasc Dis2310791085201310.1016/j.numecd.2012.12.002 ChanQStamlerJGriepLMDaviglusMLHornLVElliottPAn update on nutrients and blood pressureJ Atheroscler Thromb23276289201610.5551/jat.30000 MillerPEVan ElswykMAlexanderDDLong-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: A meta-analysis of randomized controlled trialsAm J Hypertens27885896201410.1093/ajh/hpu024 MorrisMCSacksFRosnerBDoes fish oil lower blood pressure? A meta-analysis of controlled trialsCirculation88523533199310.1161/01.CIR.88.2.523 RootMCollierSRZwetslootKAWestKLMcGinnMCA randomized trial of fish oil omega-3 fatty acids on arterial health, inflammation, and metabolic syndrome in a young healthy populationNutr J1240201310.1186/1475-2891-12-40 WangSMaAQSongSWQuanQHZhaoXFZhengXHFish oil supplementation improves large arterial elasticity in overweight hypertensive patientsEur J Clin Nutr6214261431200810.1038/sj.ejcn.1602886 UeshimaHStamlerJElliottPChanQBrownIJCarnethonMRDaviglusMLHeKMoag-StahlbergARodriguezBLINTERMAP research group: Food omega-3 fatty acid intake of individuals (total, linolenic acid, long-chain) and their blood pressure: INTERMAP studyHypertension50313319200710.1161/HYPERTENSIONAHA.107.090720 NikkariTLuukkainenPPietinenPPuskaPFatty acid composition of serum lipid fractions in relation to gender and quality of dietary fatAnn Med27491498199510.3109/07853899709002458 KatanMBDeslypereJPvan BirgelenAPPendersMZegwaardMKinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, and adipose tissue: An 18-month controlled studyJ Lipid Res38201220221997 DoughertyRMGalliCFerro-LuzziAIaconoJMLipid and phospholipid fatty acid composition of plasma, red blood cells, and platelets and how they are affected by dietary lipids: A study of normal subjects from Italy, Finland, and the USAAm J Clin Nutr454434551987 MaJFolsomARShaharEEckfeldtJHThe atherosclerosis risk in communities (ARIC) study investigators: Plasma fatty acid composition as an indicator of habitual dietary fat intake in middle-aged adultsAm J Clin Nutr625645711995 VessbyBGustafssonIBTengbladSBobergMAnderssonADesaturation and elongation of fatty acids and insulin actionAnn N Y Acad Sci967183195200210.1111/j.1749-6632.2002.tb04275.x SimonJAFongJBernertJTJrSerum fatty acids and blood pressureHypertension27303307199610.1161/01.HYP.27.2.303 GrimsgaardSBonaaKHJacobsenBKBjerveKSPlasma saturated and linoleic fatty acids are independently associated with blood pressureHypertension34478483199910.1161/01.HYP.34.3.478 ZhengZJFolsomARMaJArnettDKMcGovernPGEckfeldtJHPlasma fatty acid composition and 6-year incidence of hypertension in middle-aged adults: The atherosclerosis risk in communities (ARIC) studyAm J Epidemiol150492500199910.1093/oxfordjournals.aje.a010038 WangSMaASongSQuanQZhaoXZhengXFasting serum free fatty acid composition, waist/hip ratio and insulin activity in essential hypertensive patientsHypertens Res31623632200810.1291/hypres.31.623 WangLTsaiMMansonJEDjousseLGazianoJMBuringJESessoHDErythrocyte fatty acid composition is associated with the risk of hypertension in middle-aged and older womenJ Nutr14116911697201110.3945/jn.111.138867 YangBDingFYanJYeXWXuXLWangFLLiDYuWExploratory serum fatty acid patterns associated with blood pressure in community-dwelling middle-aged and elderly ChineseLipids Health Dis1558201610.1186/s12944-016-0226-326993260 BlighEGDyerWJA rapid method of total lipid extraction and purificationCan J Biochem Physiol37911917195910.1139/y59-09913671378 KawashimaASugawaraSOkitaMAkahaneTFukuiKHashiuchiMKataokaCTsukamotoIPlasma fatty acid composition, estimated desaturase activities, and intakes of energy and nutrient in Japanese men with abdominal obesity or metabolic syndromeJ Nutr Sci Vitaminol55400406200910.3177/jnsv.55.40019926925 IaconoJMDoughertyRMEffects of polyunsaturated fats on blood pressureAnnu Rev Nutr13243260199310.1146/annurev.nu.13.070193.0013318369147 PomposielloSIAlvaMWildeDWCarreteroOALinoleic acid induces relaxation and hyperpolarization of the pig coronary arteryHypertension31615620199810.1161/01.HYP.31.2.6159461230 SalonenJTDietary fats, antioxidants and blood pressureAnn Med23295298199110.3109/078538991091480631930920 BerryEMHirschJDoes dietary linolenic acid influence blood pressure?Am J Clin Nutr4433634019862875645 WendlandEFarmerAGlasziouPNeilAEffect of alpha linolenic acid on cardiovascular risk markers: A systematic reviewHeart92166169200610.1136/hrt.2004.05353815890766 HarrisWSMillerMTigheAPDavidsonMHSchaeferEJOmega-3 fatty acids and coronary heart disease risk: Clinical and mechanistic perspectivesAtherosclerosis1971224200810.1016/j.atherosclerosis.2007.11.00818160071 IbargurenMLópezDJEscribáPVThe effect of natural and synthetic fatty acids on membrane structure, microdomain organization, cellular functions and human healthBiochim Biophys Acta183815181528201410.1016/j.bbamem.2013.12.02124388951 PradesJFunariSSEscribáPVBarcelóFEffects of unsaturated fatty acids and triacylglycerols on phosphatidylethanolamine membrane structureJ Lipid Res4417201727200310.1194/jlr.M300092-JLR20012810821 AppelLJMillerERIIISeidlerAJWheltonPKDoes supplementation of diet with ‘fish oil’ reduce blood pressure? A meta-analysis of controlled clinical trialsArch Intern Med15314291438199310.1001/archinte.1993.004101200170038141868 GeleijnseJMGiltayEJGrobbeeDEDondersARKokFJBlood pressure response to fish oil supplementation: Metaregression analysis of randomized trialsJ Hypertens2014931499200210.1097/00004872-200208000-0001012172309 ColussiGCatenaCNovelloMBertinNSechiLAImpact of omega-3 polyunsaturated fatty acids on vascular function and blood pressure: Relevance for cardiovascular outcomesNutr Metab Cardiovasc Dis27191200201710.1016/j.numecd.2016.07.01127692558

Characteristics of group subjects.

Variable Normal (n=246) Hypertension (n=69) P-value
Age (years) 51.8±7.1 53.5±7.9 0.097
Lifestyle factors
  Physical activity (% yes) 35.3 49.1 0.067
  Smoking (% yes) 28.4 17.5 0.107
  Alcohol consumption (≥20 g/day, % yes) 44.7 52.6 0.256
  Salt intake (g/day) 8.7±2.9 8.4±3.0 0.255
Anthropometry indicators
  Body mass index (kg/m2) 25.4±3.1 25.9±2.7 0.160
  Waist circumference (cm) 90.1±8.0 91.3±6.6 0.297
  Systolic BP (mmHg) 124±10 152±10 <0.001
  Diastolic BP (mmHg) 79±8 96±10 <0.001
Biochemical parameters
  Triacylglycerol (mg/dl) 141.0±92.3 150.9±84.1 0.475
  Total-cholesterol (mg/dl) 206.5±31.0 212.1±29.5 0.182
  HDL-cholesterol (mg/dl) 53.1±13.7 54.7±13.1 0.249
  LDL-cholesterol (mg/dl) 127.6±29.3 128.9±28.6 0.429
  Glucose (mg/dl) 102±14 108±18 0.001
  Hemoglobin A1c (%) 5.2±0.5 5.5±0.5 0.022
  Insulin (µU/ml) 8.8±5.8 9.5±7.2 0.662
  HOMA-IR 2.25±1.67 2.54±2.09 0.374

Data are expressed as the mean ± standard deviation or percentage. BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HOMA-IR, homeostasis model assessment-estimated insulin resistance.

FA composition in plasma phospholipids between normal and hypertensive subjects.

Groups
FA (mol%) Normal Hypertension P-value
Myristic acid (14:0) 0.68±0.37 0.76±0.67 0.490
Palmitic acid (16:0) 32.43±3.85 32.50±3.45 0.976
Palmitoleic acid (16:1n-7) 0.64±0.40 0.71±0.35 0.076
Stearic acid (18:0) 13.61±1.49 13.68±1.24 0.727
Oleic acid (18:1n-9) 9.65±1.68 9.98±1.70 0.159
Vaccenic acid (18:1n-7) 1.68±0.66 1.68±0.52 0.589
Linoleic acid (18:2n-6) 18.51±3.18 17.34±2.67 0.004
γ-Linolenic acid (18:3n-6) 0.15±0.15 0.16±0.16 0.612
α-Linolenic acid (18:3n-3) 0.27±0.15 0.26±0.17 0.295
Arachidic acid (20:0) 0.46±0.24 0.50±0.28 0.402
Eicosadienoic acid (20:2n-6) 0.34±0.19 0.35±0.20 0.992
Dihomo-γ-linolenic acid (20:3n-6) 1.92±0.53 1.96±0.47 0.619
Arachidonic acid (20:4n-6) 6.99±1.20 7.29±1.37 0.072
Behenic acid (22:0) 0.84±0.50 0.87±0.46 0.690
Eicosapentaenoic acid (20:5n-3) 2.11±1.10 2.28±1.17 0.304
Docosadienoic acid (22:2n-6) 0.29±0.27 0.26±0.23 0.500
Lignoceric acid (24:0) 0.76±0.43 0.68±0.35 0.165
Docosapentaenoic acid (22:5n-3) 0.91±0.59 1.01±0.75 0.261
Docosahexaenoic acid (22:6n-3) 4.82±1.28 4.99±1.32 0.343
Total SFA 49.31±3.85 49.57±3.40 0.961
Total MUFA 13.98±1.76 14.16±1.78 0.574
Total PUFA 36.67±3.51 36.23±3.18 0.541
PUFA/SFA 0.76±0.28 0.74±0.11 0.719
Total n-6 PUFA 28.37±3.37 27.51±2.87 0.067
Total n-3 PUFA 8.30±2.48 8.72±2.77 0.314
n-6/n-3 3.80±1.47 3.54±1.37 0.163
D9D 0.021±0.020 0.023±0.012 0.100
D6D 0.008±0.009 0.010±0.011 0.354
D5D 3.89±1.18 3.92±1.12 0.666

Data are expressed as means ± standard deviation. FA, fatty acid; SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; D9D, δ-9 desaturase; D6D, δ-6 desaturase; D5D, δ-5 desaturase.

Multivariate adjusted ORs and 95% CI for hypertension by quartile of plasma phospholipid fatty acid composition.

Quartiles of plasma phospholipid fatty acid composition
Variable Q1 (Lowest) Q2 Q3 Q4 (Highest) P-value
Palmitic acid (16:0)
  Median (mol %) 29.15 31.09 33.36 36.88
  Subjects with/without Hyp (n) 18/61 15/64 19/60 17/62
  Unadjusted OR (95% CI) 1 (Reference) 0.79 (0.37–1.72) 1.07 (0.51–2.24) 0.94 (0.45–2.00) 0.924
  Adjusted OR (95% CI)a 1 (Reference) 0.78 (0.26–2.38) 1.07 (0.32–3.57) 0.85 (0.31–2.31) 0.987
Stearic acid (18:0)
  Median (mol %) 12.29 13.29 13.91 15.10
  Subjects with/without Hyp (n) 16/63 18/61 17/62 18/60
  Unadjusted OR (95% CI) 1 (Reference) 1.16 (0.54–2.48) 1.08 (0.50–2.33) 1.18 (0.65–2.53) 0.711
  Adjusted OR (95% CI)a 1 (Reference) 1.93 (0.67–5.51) 2.62 (0.90–7.65) 1.51 (0.46–4.98) 0.403
Palmitoleic acid (16:1n-7)
  Median (mol %) 0.28 0.52 0.71 0.97
  Subjects with/without Hyp (n) 17/62 10/69 20/59 22/56
  Unadjusted OR (95% CI) 1 (Reference) 0.53 (0.23–1.24) 1.24 (0.59–2.59) 1.43 (0.69–2.97) 0.133
  Adjusted OR (95 % CI)a 1 (Reference) 0.40 (0.12–1.38) 1.44 (0.53–3.87) 1.70 (0.65–4.48) 0.163
Oleic acid (18:1n-9)
  Median (mol %) 8.01 9.06 10.01 11.61
  Subjects with/without Hyp (n) 13/66 17/62 22/57 17/61
  Unadjusted OR (95% CI) 1 (Reference) 1.39 (0.63–3.10) 1.96 (0.91–4.24) 1.42 (0.64–3.15) 0.367
  Adjusted OR (95% CI)a 1 (Reference) 0.63 (0.23–1.71) 1.20 (0.42–3.44) 0.81 (0.28–2.41) 0.954
Linoleic acid (18:2n-6)
  Median (mol %) 15.04 17.43 18.97 21.01
  Subjects with/without Hyp (n) 25/54 20/59 12/67 12/66
  Unadjusted OR (95% CI) 1 (Reference) 0.73 (0.37–1.47) 0.39 (0.18–0.84) 0.39 (0.18–0.85) 0.006
  Adjusted OR (95% CI)a 1 (Reference) 0.55 (0.20–1.49) 0.35 (0.13–0.96) 0.17 (0.05–0.61) 0.003
γ-linolenic acid (18:3n-6)
  Median (mol %) 0.04 0.08 0.13 0.31
  Subjects with/without Hyp (n) 16/63 16/63 22/57 15/63
  Unadjusted OR (95% CI) 1 (Reference) 1.00 (0.46–2.17) 1.52 (0.73–3.18) 0.94 (0.43–2.06) 0.799
  Adjusted OR (95%CI)a 1 (Reference) 1.57 (0.53–4.62) 2.56 (0.83–7.84) 2.04 (0.65–6.39) 0.310
Dihomo-γ-linolenic acid (20:3n-6)
  Median (mol%) 1.34 1.74 2.05 2.56
  Subjects with/without Hyp (n) 15/64 18/61 20/59 16/62
  Unadjusted OR (95% CI) 1 (Reference) 1.26 (0.58–2.72) 1.44 (0.68–3.08) 1.10 (0.50–2.42) 0.791
  Adjusted OR (95% CI)a 1 (Reference) 1.29 (0.45–3.75) 1.65 (0.56–4.83) 1.01 (0.30–3.42) 0.915
AA (20:4n-6)
  Median (mol %) 5.68 6.61 7.50 8.47
  Subjects with/without Hyp (n) 15/64 8/71 28/51 18/60
  Unadjusted OR (95% CI) 1 (Reference) 0.48 (019–1.21) 2.34 (1.13–4.85) 1.28 (0.59–2.77) 0.080
  Adjusted OR (95% CI)a 1 (Reference) 0.38 (0.10–1.44) 2.07 (0.72–5.96) 2.04 (0.71–5.85) 0.047
ALA (18:3n-3)
  Median (mol %) 0.13 0.2 0.28 0.43
  Subjects with/without Hyp (n) 22/57 16/63 18/61 13/65
  Unadjusted OR (95% CI) 1 (Reference) 0.66 (0.32–1.38) 0.77 (0.37–1.57) 0.52 (0.24–1.12) 0.139
  Adjusted OR (95% CI)a 1 (Reference) 0.55 (0.21–1.43) 0.61 (0.21–1.78) 0.26 (0.07–0.95) 0.042
EPA (20:5n-3)
  Median (mol%) 0.99 1.64 2.27 3.40
  Subjects with/without Hyp (n) 16/63 16/63 15/64 22/56
EPA (20:5n-3)
  Unadjusted OR (95% CI) 1 (Reference) 1.00 (0.46–2.17) 0.92 (0.42–2.03) 1.55 (0.74–3.24) 0.218
  Adjusted OR (95% CI)a 1 (Reference) 2.00 (0.70–5.70) 1.30 (0.41–4.11) 1.38 (0.43–4.38) 0.879
DHA (22:6n-3)
  Median (mol%) 3.43 4.41 5.33 6.30
  Subjects with/without Hyp (n) 15/65 21/58 13/66 21/57
  Unadjusted OR (95% CI) 1 (Reference) 1.68 (0.78–3.61) 0.92 (0.40–2.10) 1.71 (0.80–3.67) 0.393
  Adjusted OR (95% CI)a 1 (Reference) 2.26 (0.78–6.54) 0.85 (0.25–2.95) 1.51 (0.52–4.44) 0.802
n-3 PUFA (ALA+EPA+DHA)
  Median (mol%) 5.51 7.2 8.97 11.52
  Subjects with/without Hyp (n) 17/62 16/63 13/66 23/55
  Unadjusted OR (95% CI) 1 (Reference) 0.93 (0.43–2.00) 0.72 (0.32–1.60) 1.53 (0.74–3.15) 0.259
  Adjusted OR (95% CI)a 1 (Reference) 1.43 (0.53–3.88) 0.67 (0.20–2.26) 1.21 (0.44–3.29) 0.960
Ratio of n-6 to n-3 PUFA
  Median 2.31 3.09 3.97 5.17
  Subjects with/without Hyp (n) 23/56 13/66 18/61 15/63
  Unadjusted OR (95% CI) 1 (Reference) 0.48 (0.22–1.03) 0.72 (0.35–1.47) 0.58 (0.28–1.22) 0.295
  Adjusted OR (95% CI)a 1 (Reference) 0.82 (0.25–2.64) 1.14 (0.40–3.25) 1.03 (0.36–2.99 0.843
D9D
  Median 0.0079 0.0163 0.0222 0.0326
  Subjects with/without Hyp (n) 16/63 13/66 19/60 21/57
  Unadjusted OR (95% CI) 1 (Reference) 0.78 (0.35–1.74) 1.25 (0.59–2.65) 1.45 (0.69–3.05) 0.199
  Adjusted OR (95% CI)a 1 (Reference) 0.55 (0.17–1.73) 1.36 (0.46–4.02) 1.78 (0.71–4.44) 0.141
D6D
  Median 0.002 0.0047 0.0075 0.0175
  Subjects with/without Hyp (n) 15/64 15/64 21/58 18/60
  Unadjusted OR (95% CI) 1 (Reference) 1.00 (0.45–2.22) 1.55 (0.73–3.28) 1.28 (0.59–2.77) 0.510
  Adjusted OR (95% CI)a 1 (Reference) 1.35 (0.43–4.23) 2.08 (0.71–6.07) 2.04 (0.67–6.18) 0.226
D5D
  Median 2.74 3.40 4.07 5.22
  Subjects with/without Hyp (n) 16/63 17/62 16/63 20/58
  Unadjusted OR (95% CI) 1 (Reference) 1.08 (0.50–2.33) 1.00 (0.46–2.17) 1.36 (0.64–2.87) 0.431
  Adjusted OR (95% CI)a 1 (Reference) 1.38 (0.42–4.53) 0.98 (0.27–3.62) 2.13 (0.63–7.23) 0.198

Adjusted for age, BMI, physical activity (yes or no), current smoking (yes or no), alcohol consumption (≥20 g/day or no), salt intake and serum levels of glucose and hemoglobin A1c. Hyp, hypertension; AA, arachidonic acid; ALA, α-linolenic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; BMI, body mass index; OR, odds ratio; CI, confidence interval; D9D, δ-9 desaturase; D6D, δ-6 desaturase; D5D, δ-5 desaturase.